Author:
Patel Nikunjkumar,Wisniowska Barbara,Polak Sebastian
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Piccini JP, Whellan DJ, Berridge BR, Finkle JK, Pettit SD, Stockbridge N, et al. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. Am Heart J. 2009;158(3):317–26.
2. Redfern W, Ewart L, Hammond T, Bialecki R, Kinter L, Lindgren S, et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. Toxicologist. 2010;114(S1):1081.
3. Laverty HG, Benson C, Cartwright EJ, Cross MJ, Garland C, Hammond T, et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol. 2011;163(4):675–93.
https://doi.org/10.1111/j.1476-5381.2011.01255.x
.
4. Stockbridge N, Morganroth J, Shah RR, Garnett C. Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated? Drug Saf. 2013;36(3):167–82.
https://doi.org/10.1007/s40264-013-0016-z
.
5. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89(11):1363–72.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献